Zetia Cost in Montana 2026: What You'll Actually Pay for Ezetimibe

How Much Does Zetia Cost in Montana in 2026?

Generic ezetimibe 10 mg costs roughly $15 per month at most Montana retail pharmacies in 2026 when purchased cash-pay with a discount card. Brand-name Zetia (Merck) carries a manufacturer list price of approximately $380 per month, though very few patients pay that full amount after insurance adjustments or copay programs.

The gap between list price and actual out-of-pocket cost for cholesterol drugs has widened significantly since ezetimibe lost patent exclusivity. The FDA approved the first generic ezetimibe products in 2017, and by 2026 multiple generic manufacturers compete for the same 10 mg tablet, driving retail prices down sharply. GoodRx and similar discount platforms routinely show ezetimibe 10 mg (30 tablets) below $20 at Walmart, Costco, and independent Montana pharmacies when a free savings card is presented at the counter.

Ezetimibe works by blocking the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestine, reducing dietary and biliary cholesterol absorption by roughly 54% [1]. The IMPROVE-IT trial (N=18,144) demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced LDL-C from a median of 69.5 mg/dL to 53.7 mg/dL and cut the primary composite cardiovascular endpoint by an absolute 2 percentage points (32.7% vs. 34.7%, hazard ratio 0.936, P<0.001) over a median of 6 years [2]. That clinical evidence supports ezetimibe as a cost-effective second-line lipid-lowering agent when statins alone are insufficient or not tolerated [3].

Patients who cannot tolerate statins represent a meaningful subset of the Montana population. Statin intolerance affects an estimated 5 to 10% of treated patients, with myopathy being the most cited reason [4]. For those individuals, ezetimibe at $15 per month offers a prescription-only alternative backed by a large outcomes trial, at a price point competitive with over-the-counter supplements.

Montana Medicaid Coverage for Zetia and Generic Ezetimibe

Montana Medicaid does not cover Zetia or generic ezetimibe for the hyperlipidemia adjunct indication as of 2026. This means Medicaid enrollees who need ezetimibe must either pay cash, obtain samples from their prescriber, or pursue a prior-authorization appeal.

The Montana Medicaid Preferred Drug List (PDL) prioritizes statins, specifically rosuvastatin and atorvastatin, as first-line agents for dyslipidemia. Ezetimibe is classified as a non-preferred drug without a preferred alternative pathway for most adult beneficiaries [5]. Clinicians who believe a patient has a medical necessity (documented statin intolerance, familial hypercholesterolemia, or contraindication) may submit a prior authorization request citing ACC/AHA guidelines, which recognize ezetimibe as a Class I recommendation for patients with atherosclerotic cardiovascular disease (ASCVD) who cannot achieve adequate LDL-C reduction with maximally tolerated statin therapy alone [6].

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD and high-risk features, if LDL-C remains 70 mg/dL or higher on maximally tolerated statin therapy, it is reasonable to add ezetimibe." [6] That language provides a clinically grounded basis for prior authorization submissions in Montana Medicaid cases where documentation is thorough.

Prior authorization denials can be appealed. A prescribing physician can submit labs showing inadequate LDL-C response on maximally tolerated statin therapy, alongside the ACC/AHA guideline citation and a letter of medical necessity. Montana's Medicaid fair hearing process gives patients the right to contest coverage denials under 42 CFR 431.220 [7].

For Medicaid patients who exhaust appeal options, the $15 cash-pay generic price is low enough that it may be more practical to purchase ezetimibe out-of-pocket than to spend clinical time on repeated appeals.

Which Insurance Plans Cover Zetia in Montana?

Commercial insurance coverage for ezetimibe in Montana varies by plan, but generic ezetimibe is covered by the majority of commercial formularies, typically at Tier 1 or Tier 2. Brand-name Zetia is usually placed at Tier 3 or higher, with copays ranging from $40 to $120 per month depending on the plan design.

Medicare Part D plans available in Montana through the 2026 plan year generally list generic ezetimibe as a covered drug at the Tier 2 generic level, meaning a standard copay of $5 to $15 per 30-day supply [8]. Brand Zetia on Medicare Part D typically falls at Tier 5 (specialty tier), where cost-sharing can reach 25 to 33% of the drug's negotiated price, making generic substitution the practical choice for nearly all Part D enrollees.

Employer-sponsored plans in Montana follow similar patterns. Under the ACA, preventive medications receive zero-cost-sharing when prescribed for primary prevention in line with USPSTF recommendations; however, the USPSTF currently does not list ezetimibe as a preventive statin equivalent, so cost-sharing typically applies [9]. Patients should verify their specific plan formulary at the start of each plan year, because tiering decisions change annually.

For patients on commercial plans with high ezetimibe copays, Merck's Zetia Savings Card program can reduce out-of-pocket costs for eligible commercially insured patients. The savings card does not apply to government-funded plans, including Medicare, Medicaid, or TRICARE. Generic manufacturers do not universally offer savings cards, but pharmacy discount programs fill that gap at a similar or lower price point.

Compounded Ezetimibe in Montana: Is It Legal?

Compounded ezetimibe prepared by a licensed 503A pharmacy is legal in Montana. 503A pharmacies are patient-specific compounding pharmacies operating under state pharmacy board oversight and Section 503A of the Federal Food, Drug, and Cosmetic Act [10].

A 503A pharmacy may compound ezetimibe for an individual patient when a licensed prescriber issues a valid prescription documenting a clinical rationale, such as documented intolerance to commercial tablet excipients, a need for a dose not commercially available, or inclusion in a combination formulation. Compounded ezetimibe is not FDA-approved and lacks the bioequivalence data required of generic drug approvals, so prescribers and patients should understand that potency and absorption consistency depend entirely on the compounding pharmacy's quality practices [11].

Cost is the most discussed reason patients ask about compounded ezetimibe in Montana. Some telehealth providers and compounding pharmacies offer compounded ezetimibe as part of cardiovascular support protocols at no direct medication cost to the patient, bundling the compound into a monthly membership or consultation fee. The effective out-of-pocket for the drug itself can therefore reach $0, though patients pay for the prescribing service separately.

The Montana Board of Pharmacy licenses and inspects 503A pharmacies within the state and can sanction out-of-state pharmacies that compound for Montana residents without meeting Montana-specific registration requirements [12]. Patients should confirm that any compounding pharmacy dispensing into Montana holds the appropriate non-resident compounding pharmacy license before filling a prescription.

503B outsourcing facilities, which compound in bulk without patient-specific prescriptions, are not permitted to compound ezetimibe as a commercially available drug under current FDA guidance on demonstrable difficulties for compounding, meaning the 503B route is not a legal option for ezetimibe [13].

Telehealth Prescribing of Ezetimibe in Montana

Montana permits telehealth prescribing of ezetimibe. Prescribers licensed in Montana may issue a prescription for ezetimibe following a synchronous audio-video telehealth visit that meets standard-of-care documentation requirements, including a documented cardiovascular risk assessment, recent lipid panel results, medication history, and a treatment plan [14].

Ezetimibe is not a controlled substance, so the prescribing restrictions that apply to Schedule II through V drugs under the DEA telemedicine rules do not apply here. A Montana-licensed prescriber can establish a new patient relationship via telehealth and prescribe ezetimibe without requiring an in-person visit, provided the clinical record supports the diagnosis and treatment rationale [15].

HealthRX clinicians follow a structured lipid management intake that includes a baseline lipid panel (typically obtained at a local Montana LabCorp or Quest draw site), a cardiac risk score calculation using pooled cohort equations, and a medication review before any ezetimibe prescription is issued. The ACC/AHA 10-year ASCVD risk calculator is the standard tool for this step, and results above 7.5% trigger a discussion of statin therapy first, with ezetimibe added or substituted based on patient response and tolerance [6].

Patients in rural Montana counties, where the nearest cardiologist may be hours away, benefit most from telehealth lipid management. Montana has 56 counties; approximately 30 are classified as rural or frontier by the Montana Office of Rural Health, and lipid management follow-up through telehealth reduces the travel burden without sacrificing clinical rigor [16].

The Clinical Evidence Behind Ezetimibe: Why It Gets Prescribed

Ezetimibe received FDA approval in October 2002 (NDA 021445) as an adjunct to diet to reduce LDL-C, total cholesterol, and apolipoprotein B [1]. For more than a decade after approval, the drug lacked cardiovascular outcomes data, which limited its acceptance among cardiologists who required proof that LDL reduction translated to fewer events.

The IMPROVE-IT trial resolved that question. Published in the New England Journal of Medicine in 2015 (N=18,144 post-ACS patients), IMPROVE-IT showed that simvastatin 40 mg plus ezetimibe 10 mg reduced the 7-year primary endpoint rate to 32.7% compared with 34.7% for simvastatin alone, a relative risk reduction of 6.4% (P<0.001) [2]. The NNT to prevent one major cardiovascular event was approximately 50 over 7 years, consistent with the magnitude of LDL-C lowering achieved.

Ezetimibe also has a favorable safety profile. In IMPROVE-IT, rates of hepatic enzyme elevation greater than three times the upper limit of normal were 1.0% in the combination arm versus 0.7% in the statin-alone arm, a statistically non-significant difference [2]. Rates of myopathy and rhabdomyolysis did not differ meaningfully between arms, confirming that ezetimibe does not add meaningful muscle toxicity to statin therapy [4].

For patients with familial hypercholesterolemia (FH), ezetimibe added to high-intensity statin therapy can reduce LDL-C by a further 15 to 20%, which is clinically significant when baseline LDL-C already exceeds 190 mg/dL [17]. The European Atherosclerosis Society consensus statement on FH specifies ezetimibe as a standard add-on when statin monotherapy is insufficient [18]. Montana does not have a statewide FH registry, but national prevalence estimates suggest roughly 1 in 250 individuals carries a heterozygous FH mutation, translating to approximately 4,300 Montanans [19].

What's the Cheapest Way to Get Ezetimibe in Montana?

The cheapest straightforward path to ezetimibe in Montana is generic ezetimibe 10 mg purchased cash-pay using a free GoodRx, RxSaver, or NeedyMeds discount card at a high-volume retailer such as Walmart (Billings, Missoula, Great Falls, Bozeman locations) or Costco. Cash prices at these locations range from $10 to $18 per 30-day supply in 2026 [20].

For patients who qualify for a telehealth compounding pathway, the effective medication cost may be $0, with the total expense reflecting only the telehealth subscription or consultation fee. This approach requires a valid prescription from a Montana-licensed prescriber and a licensed 503A compounding pharmacy.

Patients with commercial insurance should run a quick formulary check. Generic ezetimibe at Tier 1 on a commercial plan typically costs $5 to $10 per fill, beating even the best cash-pay discount-card price. Brand Zetia on a commercial plan is nearly always more expensive than its generic equivalent, so automatic generic substitution (permitted in Montana under its generic substitution law) is the default unless the prescriber writes "dispense as written."

Patient assistance programs represent a third option. Merck's patient assistance program (MAP) provides free Zetia to uninsured or underinsured patients who meet income criteria, generally at or below 400% of the federal poverty level [21]. Applications are submitted through NeedyMeds or directly through Merck's MAP portal. Processing takes two to four weeks, and a physician signature is required.

The NeedyMeds Drug Discount Card is available free at needymeds.org and has no eligibility requirements. In Montana test searches for ezetimibe 10 mg (30 tablets), NeedyMeds quotes prices between $11 and $17 at participating pharmacies [22].

Ezetimibe Dosing and Administration

Ezetimibe is prescribed as a 10 mg oral tablet taken once daily. Timing relative to meals does not affect absorption, and the tablet may be taken at any time of day [1]. When co-administered with a bile acid sequestrant such as cholestyramine, ezetimibe should be taken at least two hours before or at least four hours after the sequestrant to avoid reduced absorption [1].

No dose adjustment is required for patients with mild hepatic impairment (Child-Pugh A). Ezetimibe is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) due to unknown effects of increased ezetimibe exposure in this population [1]. Renal impairment does not require dose modification.

The combination tablet Vytorin (ezetimibe 10 mg plus simvastatin) provides the same ezetimibe dose in a fixed-dose formulation. Generic versions of Vytorin are available and priced comparably to taking the two generics separately; some patients prefer the single-tablet convenience [23].

Drug interactions of clinical significance include cyclosporine (increases ezetimibe AUC approximately 12-fold, requiring close monitoring), fenofibrate (modest increase in ezetimibe exposure), and the warfarin interaction (ezetimibe has not been found to significantly alter INR in clinical studies, but monitoring is prudent when initiating therapy in anticoagulated patients) [1].

Monitoring LDL-C After Starting Ezetimibe

A repeat fasting lipid panel four to twelve weeks after initiating ezetimibe is standard practice, per ACC/AHA 2018 guidelines [6]. This interval allows assessment of both efficacy (LDL-C reduction of 15 to 25% from baseline is the expected range) and early detection of hepatic enzyme elevation, though routine liver function testing is not required unless symptoms arise.

LDL-C goals depend on baseline cardiovascular risk. For patients with established ASCVD, the ACC/AHA guideline recommends an LDL-C below 70 mg/dL; for very-high-risk patients (multiple ASCVD events or ASCVD plus multiple high-risk conditions), an LDL-C below 55 mg/dL is the target [6]. If ezetimibe added to maximally tolerated statin fails to reach these targets, PCSK9 inhibitor therapy (alirocumab or evolocumab) represents the next escalation step, though monthly injection costs in Montana range from $450 to $600 before manufacturer savings programs [24].

Adherence to ezetimibe is high relative to statins, partly because ezetimibe lacks the muscle-related side effects that cause many patients to discontinue statin therapy. In a meta-analysis of 27 randomized controlled trials (N=20,007), ezetimibe discontinuation rates did not differ significantly from placebo (relative risk 1.02 to 95% CI 0.94 to 1.10) [25].